Crinetics Pharmaceuticals (CRNX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Key Insights
Critical company metrics and information
Share Price
$56.62Market Cap
$5.25 BillionTotal Outstanding Shares
92.74 Million SharesTotal Employees
210Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.crinetics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $20.60 Million |
Net Cash Flow From Investing Activities | $20.60 Million |
Net Cash Flow From Operating Activities, Continuing | $-62.82 Million |
Net Cash Flow From Operating Activities | $-62.82 Million |
Net Cash Flow From Financing Activities, Continuing | $57.33 Million |
Net Cash Flow, Continuing | $15.11 Million |
Net Cash Flow | $15.11 Million |
Net Cash Flow From Financing Activities | $57.33 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Costs And Expenses | $87.80 Million |
Operating Expenses | $87.80 Million |
Basic Earnings Per Share | $-0.96 |
Revenues | $0.00 |
Diluted Earnings Per Share | $-0.96 |
Net Income/Loss | $-76.83 Million |
Research and Development | $61.91 Million |
Diluted Average Shares | $80.09 Million |
Income/Loss From Continuing Operations Before Tax | $-76.83 Million |
Income/Loss From Continuing Operations After Tax | $-76.83 Million |
Operating Income/Loss | $-87.80 Million |
Benefits Costs and Expenses | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Attributable To Parent | $-76.83 Million |
Other Operating Expenses | $25.89 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-76.83 Million |
Depreciation and Amortization | $770,000.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Nonoperating Income/Loss | $10.97 Million |
Basic Average Shares | $80.09 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Fixed Assets | $11.71 Million |
Other Non-current Assets | $48.08 Million |
Noncurrent Liabilities | $50.83 Million |
Other Current Liabilities | $48.62 Million |
Noncurrent Assets | $59.79 Million |
Liabilities And Equity | $937.37 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $53.56 Million |
Current Assets | $877.59 Million |
Other Current Assets | $14.89 Million |
Equity Attributable To Parent | $832.98 Million |
Assets | $937.37 Million |
Liabilities | $104.39 Million |
Cash | $862.70 Million |
Equity | $832.98 Million |
Accounts Payable | $4.94 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.